TOTAL SALES | GROWTH PLATFORMS | NEW MEDICINES |
Q1 2024 | €822m |
HIGHLIGHTS | +13.3% |
"An excellent | Oncology | |
first-quarter | ||
Rare Disease | ||
performance has | Neuroscience | |
laid a solid | ||||
foundation for | FY 2024 | |||
Ipsen's growth | GUIDANCE1 | |||
in 2024." | CONFIRMED | |||
Total- | Core | |||
David Loew | sales | operating | ||
growth | margin | |||
Chief Executive Officer | greater than | greater than | ||
6.0% | 30.0% | |||
(at constant | of | |||
exchange | total | |||
rates) | sales |
+19.3% | +22.2% | €26m | €12m |
+29.8% | +2.6% | €7m |
GEOGRAPHIC BREAKDOWN | PIPELINE UPDATE |
Q1 2024 TOTAL SALES BY REGION |
33% | 38% | 29% | Regulatory approval and |
launch of Onivyde in the | |||
North America | Europe | Rest of World | U.S. as a first-line |
treatment for metastatic | |||
pancreatic ductal | |||
adenocarcinoma | |||
Two pre-clinical | |||
transactions |
All growth rates are at constant exchange rates.
1 Excludes any impact of any additional late-stage (Phase III clinical development or later) external-innovation opportunities and incorporates expectations for Somatuline of further generic lanreotide products in the U.S & E.U - expected adverse impact of ~1%
from currencies on sales, based on average level of exchange rates in March 2024.
For further information on Ipsen's Q1 2024 sales update and definitions of financial indicators, please refer to the press release at:
www.ipsen.com/investors
Craig Marks | Nicolas Bogler |
Vice President, Investor Relations | Senior Manager, Investor Relations |
+44 7584 349 193 | +33 6 52 19 98 92 |
craig.marks@ipsen.com | nicolas.bogler@ipsen.com |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ipsen SA published this content on 24 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 April 2024 05:31:06 UTC.